<p>Elevance Health (ELV) 再次成为焦点，因为 2026 年第一季度的业绩显示调整后的每股收益为 12.58 美元，同比增长 5.1%，管理层上调了全年调整后的每股收益指引。</p>
<p>查看我们对 Elevance Health 的最新分析。</p>
<p>第一季度的业绩和指引升级与股票的强劲势头相吻合，1 个月的股价回报为 14.5%，3 个月的股价回报为 17.5%，而 3 年的总股东回报仍然较低。</p>
<p>如果 Elevance Health 的动态引起了你的注意，了解医疗行业其他公司的动向也很有用，包括那些通过 34 只医疗 AI 股票在护理交付和分析中运用 AI 的公司。</p>
<p>Elevance Health 预计 2026 年调整后的每股收益至少为 26.75 美元，而在最近强劲的表现后，股价接近 394.69 美元，目前的估值是否仍然给你提供安全边际，还是市场已经在定价未来的增长？</p>
<h2>最受欢迎的叙述：高估 1.1%</h2>
<p>Elevance Health 的最新叙述公允价值为 390.54 美元，略低于最后收盘价 394.69 美元，这使得该股票几乎与该估计相符。</p>
<blockquote>
<p><em>作为潜在的增长投资，Elevance Health 被描述为提供低估值和长期增长驱动因素的组合，特别是在医疗保险优势和基于价值的护理领域。尽管短期风险如医疗补助注册人数下降和成本压力带来了挑战，但其多元化的收入基础和对创新的关注被认为是其韧性的来源。战略时机和对市场及运营趋势的密切监控被认为对未来 1-3 年的潜在增长至关重要。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>好奇叙述公允价值与今天价格之间几乎平坦的差距背后是什么？叙述主要依赖于收益复合、利润率韧性和不典型于成熟保险公司的未来利润倍数。医疗补助的逆风与医疗保险优势的预期之间的紧张关系直接反映在这些现金流路径和折现假设中。如果你想确切了解这些动态如何对齐以达到 390.54 美元的数字，完整的叙述将以简单的数字进行分解。</p>
<p><strong>结果：公允价值 390.54 美元（高估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，如果医疗补助压力持续或医疗成本保持高位，叙述可能会迅速转变，这将压缩利润率，超出当前公允价值的暗示。</p>
<p>了解 Elevance Health 叙述的关键风险。</p>
<h2>另一种观点：倍数描绘了更便宜的画面</h2>
<p>叙述公允价值将 Elevance Health 标记为高估 1.1%，然而市场以 16.3 倍的市盈率定价该股票，而同行的市盈率接近 36.9 倍，公允比率为 31.3 倍。这一巨大差距表明投资者要么保持谨慎，要么放弃了一些机会，因此引发了你想要站在哪一边的问题。</p>
<p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24a7ba32-6bf4-4528-b058-789c264bb1e1/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24a7ba32-6bf4-4528-b058-789c264bb1e1/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTI0"/></p>
<p>截至 2026 年 5 月的 NYSE:ELV 市盈率</p>
<h2>下一步</h2>
<p>在对公允价值的轻微溢价和看起来更便宜的市盈率之间情绪分裂的时刻，是时候自己审查数字并迅速行动。要了解投资者对什么持乐观态度，请查看 4 个关键回报。</p>
<h2>寻找更多投资想法？</h2>
<p>如果 Elevance Health 让你考虑投资组合升级，现在是扫描其他机会的时机，而不是等待下一个头条新闻。</p>
<ul>
<li>通过检查被筛选为高质量且不受欢迎的公司，提前发现潜在的便宜货，这些公司包含在 21 个高质量未被发现的宝藏中。</li>
<li>通过审查被突出为潜在收益工作的股票，增强你的收入流，这些股票被称为 10 个股息堡垒。</li>
<li>通过关注那些在 67 只低风险股票中表现出韧性的公司，保持风险在可控范围内。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，性质一般。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在任何提到的股票中没有持仓。</em></p>
<h3>估值是复杂的，但我们在这里简化它。</h3>
<p>通过我们的详细分析，发现 Elevance Health 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

美国医疗保健供应商 ETF - iShares

<p>Elevance Health (ELV) 报告了 2026 年第一季度调整后的每股收益为 12.58 美元，同比增长 5.1%，因此提高了全年每股收益指引。过去一个月，该股回报率为 14.5%。当前的公允价值估计为 390.54 美元，表明该股在 394.69 美元时被高估了 1.1%。尽管面临短期风险，该公司被视为潜在的增长投资，特别是在医疗保险优势领域。建议投资者审查估值指标和市场趋势，以做出明智的决策</p>

<p>Elevance Health (ELV) is back in focus after first quarter 2026 results showed adjusted EPS of $12.58, a 5.1% year-over-year increase, and management raised full year adjusted EPS guidance.</p>
<div class="lb-trans"><p>Elevance Health (ELV) 再次成为焦点，因为 2026 年第一季度的业绩显示调整后的每股收益为 12.58 美元，同比增长 5.1%，管理层上调了全年调整后的每股收益指引。</p>
</div><p>See our latest analysis for Elevance Health.</p>
<div class="lb-trans"><p>查看我们对 Elevance Health 的最新分析。</p>
</div><p>The first quarter numbers and guidance upgrade have coincided with stronger momentum in the stock, with a 14.5% 1 month share price return and 17.5% 3 month share price return, while the 3 year total shareholder return is still lower.</p>
<div class="lb-trans"><p>第一季度的业绩和指引升级与股票的强劲势头相吻合，1 个月的股价回报为 14.5%，3 个月的股价回报为 17.5%，而 3 年的总股东回报仍然较低。</p>
</div><p>If Elevance Health’s move has caught your eye, it can be useful to see what else is moving in healthcare, including companies working with AI in care delivery and analytics via the 34 healthcare AI stocks</p>
<div class="lb-trans"><p>如果 Elevance Health 的动态引起了你的注意，了解医疗行业其他公司的动向也很有用，包括那些通过 34 只医疗 AI 股票在护理交付和分析中运用 AI 的公司。</p>
</div><p>With Elevance Health guiding to at least $26.75 in adjusted EPS for 2026 and the stock near $394.69 after a strong recent run, is the current valuation still giving you a margin of safety, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>Elevance Health 预计 2026 年调整后的每股收益至少为 26.75 美元，而在最近强劲的表现后，股价接近 394.69 美元，目前的估值是否仍然给你提供安全边际，还是市场已经在定价未来的增长？</p>
</div><h2>Most Popular Narrative: 1.1% Overvalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：高估 1.1%</h2>
</div><p>The latest narrative fair value for Elevance Health sits at $390.54, slightly below the last close of $394.69, which puts the stock almost in line with that estimate.</p>
<div class="lb-trans"><p>Elevance Health 的最新叙述公允价值为 390.54 美元，略低于最后收盘价 394.69 美元，这使得该股票几乎与该估计相符。</p>
</div><blockquote>
<p><em>As a potential growth investment, Elevance Health is described as offering a mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation are noted as sources of resilience. Strategic timing and close monitoring of market and operational trends are presented as important to any attempt to capitalize on potential growth over the next 1-3 years.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>作为潜在的增长投资，Elevance Health 被描述为提供低估值和长期增长驱动因素的组合，特别是在医疗保险优势和基于价值的护理领域。尽管短期风险如医疗补助注册人数下降和成本压力带来了挑战，但其多元化的收入基础和对创新的关注被认为是其韧性的来源。战略时机和对市场及运营趋势的密切监控被认为对未来 1-3 年的潜在增长至关重要。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Curious what sits behind that almost flat gap between narrative fair value and today’s price? The narrative leans heavily on earnings compounding, margin resilience and a future profit multiple that is not typical for a mature insurer. The tension between Medicaid headwinds and Medicare Advantage expectations is reflected directly in those cash flow paths and discount assumptions. If you want to see exactly how those moving parts line up to reach that $390.54 figure, the full narrative breaks it down in plain numbers.</p>
<div class="lb-trans"><p>好奇叙述公允价值与今天价格之间几乎平坦的差距背后是什么？叙述主要依赖于收益复合、利润率韧性和不典型于成熟保险公司的未来利润倍数。医疗补助的逆风与医疗保险优势的预期之间的紧张关系直接反映在这些现金流路径和折现假设中。如果你想确切了解这些动态如何对齐以达到 390.54 美元的数字，完整的叙述将以简单的数字进行分解。</p>
</div><p><strong>Result: Fair Value of $390.54 (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值 390.54 美元（高估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, the narrative could shift quickly if Medicaid pressures persist or if medical costs stay elevated, which would squeeze margins more than the current fair value implies.</p>
<div class="lb-trans"><p>然而，如果医疗补助压力持续或医疗成本保持高位，叙述可能会迅速转变，这将压缩利润率，超出当前公允价值的暗示。</p>
</div><p>Find out about the key risks to this Elevance Health narrative.</p>
<div class="lb-trans"><p>了解 Elevance Health 叙述的关键风险。</p>
</div><h2>Another View: Multiples Paint a Cheaper Picture</h2>
<div class="lb-trans"><h2>另一种观点：倍数描绘了更便宜的画面</h2>
</div><p>The narrative fair value pegs Elevance Health as 1.1% overvalued, yet the market is pricing the stock at a P/E of 16.3x, while peers trade closer to 36.9x and the fair ratio sits at 31.3x. That wide gap suggests investors are either being cautious or leaving something on the table, so it raises the question of which side of that trade you want to be on.</p>
<div class="lb-trans"><p>叙述公允价值将 Elevance Health 标记为高估 1.1%，然而市场以 16.3 倍的市盈率定价该股票，而同行的市盈率接近 36.9 倍，公允比率为 31.3 倍。这一巨大差距表明投资者要么保持谨慎，要么放弃了一些机会，因此引发了你想要站在哪一边的问题。</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24a7ba32-6bf4-4528-b058-789c264bb1e1/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTI0" alt="" original-src="https://images.simplywall.st/company/24a7ba32-6bf4-4528-b058-789c264bb1e1/chart/pe-multiple-vs-industry?date=2026-05-24"/></p>
<p>NYSE:ELV P/E Ratio as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 NYSE:ELV 市盈率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>With sentiment split between a slight premium to fair value and a cheaper looking P/E, this is a moment to review the numbers yourself and move quickly. To see what investors are optimistic about, check out the 4 key rewards</p>
<div class="lb-trans"><p>在对公允价值的轻微溢价和看起来更便宜的市盈率之间情绪分裂的时刻，是时候自己审查数字并迅速行动。要了解投资者对什么持乐观态度，请查看 4 个关键回报。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Elevance Health has you thinking about portfolio upgrades, now is the time to scan for other opportunities rather than wait for the next headline.</p>
<div class="lb-trans"><p>如果 Elevance Health 让你考虑投资组合升级，现在是扫描其他机会的时机，而不是等待下一个头条新闻。</p>
</div><ul>
<li>Spot potential bargains early by checking companies that screen as high quality and unloved through the screener containing 21 high quality undiscovered gems.</li>
<li>Strengthen your income stream by reviewing stocks highlighted as potential yield workhorses via the 10 dividend fortresses.</li>
<li>Keep risk in check by focusing on companies that stand out for resilience using the 67 resilient stocks with low risk scores.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过检查被筛选为高质量且不受欢迎的公司，提前发现潜在的便宜货，这些公司包含在 21 个高质量未被发现的宝藏中。</li>
<li>通过审查被突出为潜在收益工作的股票，增强你的收入流，这些股票被称为 10 个股息堡垒。</li>
<li>通过关注那些在 67 只低风险股票中表现出韧性的公司，保持风险在可控范围内。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，性质一般。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在任何提到的股票中没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里简化它。</h3>
</div><p>Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Elevance Health 是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

Elevance Health (ELV) 的估值分析：强劲的盈利增长后，每股收益指引上调